The consensus 12-month price target for Argenx implies 23% potential share-price upside; analysts cite 18 consecutive quarters of revenue growth and upcoming pipeline catalysts. Global product sales rose 60% year over year to $1.5 billion in Q2 2026.
Argenx’s Vyvgart franchise, including Vyvgart Hytrulo, treats generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). A May 2026 FDA label expansion made the therapies the first and only approved treatments for all serotypes in adults with gMG. About 24,000 U.S. patients are treated for CIDP, and roughly half are not considered well managed on their current therapy.
Argenx reported positive Phase 3 results for Vyvgart in ocular myasthenia gravis; CEO Karen Massey said the company was moving forward with urgency on a filing. Positive late-stage results for Vyvgart Hytrulo in autoimmune myositis also set up a potential filing. Results from an empasiprubart study for multifocal motor neuropathy are expected in Q4 2026, with four more registrational-study results due in 2027. Twenty analysts rate the stock Buy, but Robert W. Baird analyst Colleen M. Kusy recommends Hold; disappointing clinical data remain a risk.
